Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -514.51 Thousand USD | -510.41% |
| 2022 | 125.36 Thousand USD | 115.7% |
| 2021 | 58.12 Thousand USD | -42.13% |
| 2020 | 100.42 Thousand USD | -53.67% |
| 2019 | 216.77 Thousand USD | 208.22% |
| 2018 | 70.33 Thousand USD | 576.48% |
| 2017 | -14.76 Thousand USD | 6.77% |
| 2016 | -15.83 Thousand USD | -852.88% |
| 2015 | 2103.00 USD | -75.85% |
| 2014 | 8707.00 USD | -2.2% |
| 2013 | 8903.00 USD | 100.58% |
| 2012 | -1.52 Million USD | -3301.11% |
| 2011 | 47.76 Thousand USD | -21.16% |
| 2010 | 60.58 Thousand USD | 0.98% |
| 2009 | 60 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -161.98 Thousand USD | -2.43% |
| 2024 Q1 | -158.13 Thousand USD | 0.39% |
| 2023 Q4 | -158.76 Thousand USD | -23009.52% |
| 2023 Q1 | 83.54 Thousand USD | -28.35% |
| 2023 Q3 | 693.00 USD | 100.59% |
| 2023 Q2 | -116.52 Thousand USD | -239.48% |
| 2023 FY | -514.51 Thousand USD | -510.41% |
| 2022 Q3 | 6933.00 USD | 2496.63% |
| 2022 Q1 | 1568.00 USD | 118.35% |
| 2022 FY | 125.36 Thousand USD | 115.7% |
| 2022 Q4 | 116.59 Thousand USD | 1581.77% |
| 2022 Q2 | 267.00 USD | -82.97% |
| 2021 Q2 | 29.78 Thousand USD | -7.49% |
| 2021 FY | 58.12 Thousand USD | -42.13% |
| 2021 Q1 | 32.19 Thousand USD | 190.56% |
| 2021 Q4 | -8545.00 USD | -282.31% |
| 2021 Q3 | 4687.00 USD | -84.26% |
| 2020 Q1 | 63.42 Thousand USD | -37.37% |
| 2020 FY | 100.42 Thousand USD | -53.67% |
| 2020 Q2 | 33.33 Thousand USD | -47.45% |
| 2020 Q3 | 39.22 Thousand USD | 17.67% |
| 2020 Q4 | -35.54 Thousand USD | -190.64% |
| 2019 Q4 | 101.26 Thousand USD | 124.47% |
| 2019 FY | 216.77 Thousand USD | 208.22% |
| 2019 Q1 | 37.24 Thousand USD | 9.33% |
| 2019 Q2 | 33.15 Thousand USD | -10.97% |
| 2019 Q3 | 45.11 Thousand USD | 36.07% |
| 2018 Q3 | 16.99 Thousand USD | 38.12% |
| 2018 Q1 | 6972.00 USD | -99.47% |
| 2018 FY | 70.33 Thousand USD | 576.48% |
| 2018 Q4 | 34.06 Thousand USD | 100.44% |
| 2018 Q2 | 12.3 Thousand USD | 76.48% |
| 2017 Q2 | -1.32 Million USD | -137.84% |
| 2017 Q1 | -557.51 Thousand USD | -127.77% |
| 2017 FY | -14.76 Thousand USD | 6.77% |
| 2017 Q4 | 1.32 Million USD | 0.0% |
| 2017 Q3 | - USD | 100.0% |
| 2016 Q3 | -912.58 Thousand USD | 0.0% |
| 2016 Q1 | - USD | 100.0% |
| 2016 Q4 | 2 Million USD | 320.01% |
| 2016 FY | -15.83 Thousand USD | -852.88% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q3 | -400.00 USD | -168.73% |
| 2015 FY | 2103.00 USD | -75.85% |
| 2015 Q4 | -6427.00 USD | -1506.75% |
| 2015 Q2 | 582.00 USD | -69.7% |
| 2015 Q1 | 1921.00 USD | 104.24% |
| 2014 Q2 | 10.51 Thousand USD | 12.9% |
| 2014 FY | 8707.00 USD | -2.2% |
| 2014 Q1 | 9311.00 USD | 4.58% |
| 2014 Q4 | -45.32 Thousand USD | -1041.8% |
| 2014 Q3 | 4813.00 USD | -54.21% |
| 2013 Q4 | 8903.00 USD | 100.46% |
| 2013 FY | 8903.00 USD | 100.58% |
| 2013 Q1 | -1.02 Million USD | -1483.7% |
| 2013 Q2 | -1.5 Million USD | -46.97% |
| 2013 Q3 | -1.93 Million USD | -28.39% |
| 2012 Q4 | 74.1 Thousand USD | 106.14% |
| 2012 FY | -1.52 Million USD | -3301.11% |
| 2012 Q1 | -3570.00 USD | -135.7% |
| 2012 Q2 | -848.05 Thousand USD | -23655.1% |
| 2012 Q3 | -1.2 Million USD | -42.32% |
| 2011 Q3 | 10 Thousand USD | 0.0% |
| 2011 FY | 47.76 Thousand USD | -21.16% |
| 2011 Q4 | 10 Thousand USD | 0.0% |
| 2010 FY | 60.58 Thousand USD | 0.98% |
| 2010 Q4 | 10 Thousand USD | 0.0% |
| 2010 Q3 | 10 Thousand USD | 0.0% |
| 2009 FY | 60 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -20995.121% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 104.395% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -61.032% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.432% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 98.006% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -966.143% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -314.089% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 103.43% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 16686.396% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 105.253% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 882.787% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -1406.618% |
| Mesoblast Limited | -35.16 Million USD | 98.537% |
| Marizyme, Inc. | 457.7 Thousand USD | 212.412% |
| Genus plc | 178.7 Million USD | 100.288% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.234% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 926.841% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 225.44% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -4577.364% |
| ContraFect Corporation | -154 Thousand USD | -234.097% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -929.02% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 770.275% |
| IMV Inc. | -962.29 Thousand USD | 46.533% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -32.776% |
| MultiCell Technologies, Inc. | 49.32 USD | 1043307.624% |
| ONE Bio Corp. | 20.12 Million USD | 102.557% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 101.278% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 1152.168% |
| Q BioMed Inc. | -8988.00 USD | -5624.41% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 101.821% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -3235.775% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 101.16% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 54.93% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 835.014% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -10289.943% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 466.199% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -427.621% |
| GB Sciences, Inc. | -624.00 USD | -82353.526% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -498.073% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.007% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -247260.577% |
| Enzolytics Inc. | 30.7 Thousand USD | 1775.492% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 206.649% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.046% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 183.337% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.126% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -5709.734% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -513.615% |
| Kadimastem Ltd | -630.13 Thousand USD | 18.35% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 152.077% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 105.353% |
| BioStem Technologies, Inc. | 15.42 Million USD | 103.336% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -4247.36% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 391.408% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 391.408% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 137.911% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -1674.172% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 214.325% |
| SYBLEU INC | 11.69 Thousand USD | 4499.025% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 111.166% |
| Bioxytran, Inc. | -8285.00 USD | -6110.139% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -37.938% |
| Neutra Corp. | 14.33 Thousand USD | 3689.187% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -527.451% |
| PureTech Health plc | -1.6 Million USD | 67.903% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 48.613% |
| IXICO plc | 3.27 Million USD | 115.734% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 25.863% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 71.272% |
| CSL Limited | 7.7 Billion USD | 100.007% |
| Cellectis S.A. | 18 Thousand USD | 2958.389% |